botic genetic mutations including factor V Leiden (FVL) (612309.001) and prothrombin G20210A (176930.0009) when treating patients who have had or are at risk of venous thromboembolism (VTE). Factor V Leiden refers to a single base change in the factor V gene (G1691A) that eliminates 1 of its 3 activated protein C cleavage sites. Consequently, factor V is inactivated at a lower rate, leading to more thrombin generation.
mozygotes. In 2003, the US Food and Drug Administration approved the first DNA-based laboratory tests specifically for FVL and prothrombin G20210A detection (Roche LightCycler Tag-IT Mutation Detection Method; Roche Diagnostics, Indianapolis, Indiana). Testing for these mutations is widely offered in the United States.
The Evaluation of Genomic ApplicationsinPracticeandPrevention(EGAPP) initiative was developed by the Centers for Disease Control and Prevention to address the need for timely and objective evidence that allows health care providers and payers, policy makers, and consumers to identify genetic tests that are safe and useful. On their behalf, and as a part of an Agency for Healthcare Research and Quality-supported EvidenceBased Practice Center, we conducted a broad review of testing for FVL and prothrombin G20210A. 4 We systematically reviewed the published literature on the predictive value of these genetic tests for future VTE in 2 populations: individuals with a history of VTE (probands) and family members of individuals with VTE and 1 of the mutations. We also assessed whether testing adults with VTE for these mutations improves outcomes.
METHODS

Search Strategy
We performed our search electronically, by hand, and through discussion with experts. We searched 5 
Study Selection
Two authors independently reviewed titles and abstracts to identify eligible articles.Abstractswereexcludedwhenboth investigators agreed they were not relevant, did not study adults, included no originaldata,orwerenotpublishedinEnglish. Full articles underwent independentparallelreviewtodeterminetheirappropriateness. Studies about the predictive value of the genetic tests were excluded if they did not report results separately for individuals with each mutation, did not objectively confirm VTE, studiedfewerthan10probandsor10fam-ily members of individuals with mutations, or did not prospectively study probands. Retrospective studies of family memberswereacceptable.Studiesofpregnantwomenwereexcluded.Studiesusing qualitative methods were excluded if less than 80% of the participants had either mutation or a history of VTE.
Data Abstraction
A primary reviewer completed all data abstraction forms. A second reviewer with clinical expertise checked the results for completeness and accuracy. Reviewers were not masked to the articles' authors, institutions, or journal. 5 We abstracted information on study characteristics, population characteristics, objective of the study, and results. When available, we noted whether the index VTEs were idiopathic events; ie, without identifiable precipitants. Information was entered into the SRS 4.0 database (TrialStat! Corp, Ottawa, Ontario, Canada).
Study Quality Assessment
Two investigators independently assessed articles' internal validity based on study setting, inclusion/exclusion a Number of excluded articles sums to more than total number because articles could be excluded for more than 1 reason at this level. b Forty articles addressed the predictive value of testing and 9 addressed the effect of testing; 3 of these articles addressed both. criteria, key characteristics of the enrolled participants, losses to followup, and funding source. Our quality assessment of qualitative studies included items from the Joanna Briggs Institute Qualitative Assessment and Review Instrument. 6 A senior reviewer adjudicated the discrepancies in the quality assessment. Quality assessments are presented descriptively rather than quantitatively to highlight potential sources of bias.
Data Synthesis
We quantitatively pooled data from studies that assessed the predictive value of the tests when there were sufficient data and the studies were qualitatively homogeneous with respect to key variables. We calculated a pooled estimate of the odds ratio (OR) for VTE in probands and separately in family members. We used a random-effects model with the DerSimonian and Laird method for calculating between-study variance. 7 Fixed-effects models yielded very similar results.
We assessed heterogeneity among the studies using a standard 2 test and a significance level of ␣Յ.10 and with an I 2 statistic. The I 2 statistic describes variability in effect estimates that is due to heterogeneity rather than chance. 8 A value greater than 50% suggests substantial variability.
We used the Duval and Tweedie nonparametric "trim-and-fill" method of accounting for publication bias. 9 We also used the Egger test to evaluate the likelihood of missing studies, with PϽ.05 for the bias estimate as an indicator of potentially missing studies 10 Finally, we sequentially removed each study from the calculation of the pooled estimates and recalculated the pooled ORs with a 95% confidence interval (CI). We used STATA (Intercooled, version 9.0, Stata Corp, College Station, Tex).
We graded the quantity, quality, and consistency of the evidence by adapting a grading scheme recommended by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group.
11 For each question, we assessed the strength of the study designs; the quality and consistency of the body of evidence, including limitations affecting individual study quality; certainty regarding the directness of the observed effects across studies; and the precision and strength of the findings.
RESULTS
The literature search identified 7777 unique titles, including 165 found by hand searching. We included 46 articles (FIGURE 1).
Risk of Recurrent Thrombosis Among Probands With FVL and Prothrombin G20210A vs Individuals Without the Mutations
Twenty-three articles addressed this question. Study quality was moderate (TABLE 1). There was often insufficient description of modifiers of the relationship between the mutation and recurrent VTE, such as age and other thrombotic risk factors. However, in studies using multivariate models, statistical adjustment did not generally attenuate the mutation-specific effect size. [12] [13] [14] [15] [16] Funding sources were rarely described.
Thirteen studies described rates of recurrent VTE in probands heterozygous for FVL compared with probands without mutations [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] (TABLE 2) . One presented data separately for 2 treatment groups (ximelagatran extended prophylaxis vs placebo). 22 One study tested whether FVL homozygosity is associated with a higher rate of VTE recurrence than FVL heterozygosity. 26 Overall, 979 heterozygous individuals experienced 161 recurrent VTE events and 3751 mutation-free individuals had 473 thrombotic events. The pooled OR for recurrent thrombosis was 1.56 (95% CI, 1.14-2.12) for individuals heterozygous for FVL compared with patients without the mutation (FIGURE 2A). The I 2 value was 48%, but there was no significant evidence of publication bias. When each study was sequentially removed, the ORs changed little. In the 3 studies reporting annualized event rates in individuals heterozygous for FVL, event rates ranged from 2.8% to 7.5%. 16, 19, 26 Annualized event rates in individuals without FVL ranged from 1.1% to 3.1%. 16, 19, 23 When we included 3 studies that did not specify whether the probands were heterozygous or homozygous for FVL, the OR changed little (OR, 1.61; 95% CI, 1.24-2.10). 16, 19, 27 Seven studies described rates of recurrent VTE in probands homozygous for FVL compared with those without mutations. 13, 14, 17, 20, [22] [23] [24] Overall, 49 homozygous individuals had 7 recurrent thrombotic events and 2333 mutation-free controls had 225 thrombotic events. The pooled OR was 2.65 (95% CI, 1.18-5.97) ( Figure 2B and Table 2 ). There was no evidence of heterogeneity (I 2 = 0%). When each study was sequentially removed from analysis, the ORs changed little.
Among 6 studies that included only patients with idiopathic index thromboses 16, 18, 23, 24 or reported results separately for individuals with idiopathic index events, 15, 28 the pooled OR for recurrence of VTE was 1.17 (95% CI, 0.63-2.18) for individuals with FVL relative to individuals without. One of 28 ; the others studied heterozygous individuals. A single study described recurrence rates of VTE among individuals with vs without FVL who had a clearly provoked (nonidiopathic) VTE. Results of this study showed an OR of 6.5 (95% CI, 2.5-18). 15 Three articles described rates of recurrent VTE in individuals with both the FVL and the prothrombin G20210A mutation compared with mutationfree control patients. 15, 17, 25 Overall, 10 double-heterozygous individuals had 4 recurrent events and 833 mutationfree controls had 95 recurrent thromboses. The pooled OR was 4.81 (95% CI, 0.50-46.3). In 1 study, all 3 double heterozygotes developed recurrent thrombosis. 25 Annual incidence rates were not reported in these studies. One additional study described recurrent VTE rates in double-heterozygous individuals but did not include a mutation-free comparison group. 29 Eighteen articles examined rates of recurrent VTE in probands with the prothrombin G20210A mutation [12] [13] [14] [15] 17, 18, [21] [22] [23] [24] [25] [27] [28] [29] [30] [31] [32] [33] (Table 2) . Nine articles compared rates of recurrent VTE between probands heterozygous for prothrombin G20210A and mutationfree probands. 14, 15, 17, 19, [21] [22] [23] [24] [25] The number of probands with a heterozygous prothrombin G20210A mutation ranged from 3 to 58 (median, 26). The number of comparison probands ranged from 72 to 724 (median, 307). Among 281 probands heterozygous for the prothrombin G20210A mutation, 38 recurrent thrombotic events occurred compared with 385 recurrent events among 3355 mutation-free probands. The pooled OR was 1.45 (95% CI, 0.96-2.21) ( Figure 2C ). The I 2 for heterogeneity was 8% and there was no evidence of publication bias. In our sensitivity analysis, removal of 1 study with an OR of 4.0 15 decreased the pooled OR to 1.30. Annual recurrence rates were reported in 2 studies and were 0% and 2.9%.
19, 24 One additional study reported a relative rate that did not differ significantly from unity but did not report numbers of recurrent VTE events. 32 When 4 studies were included that did not specify whether probands were heterozygous or homozygous, the combined OR was 1.23 (95% CI, 0.87-1.7). 27 Only 2 articles quantified event rates in individuals with VTE who were homozygous for prothrombin G20210A compared with mutation-free probands. 22, 24 There were only 3 probands homozygous for prothrombin Size of the data markers is proportional to study size. CI indicates confidence interval. G20210A in these studies, and none developed recurrent thrombosis.
Family Members With FVL and Prothrombin G20210A and Risk of Thrombosis vs Family Members Without the Mutations
Seventeen articles [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] assessed first venous thrombosis in family members of individuals with the FVL or prothrombin G20210A mutations (TABLE 3) . Study quality was mixed. Inclusion criteria other than that participants be family members of probands with VTE were not always stated. Three of the 5 prospective studies conducted clinical surveillance for VTE either annually or biannually. [35] [36] [37] Studies varied in their descriptions of the population from which participants were identified. Several had little description of eligibility criteria for family members. [38] [39] [40] [41] Age and sex were inconsistently described.
Nine studies described rates of VTE in relatives with heterozygosity for FVL compared with relatives without the mutation. [35] [36] [37] [41] [42] [43] [44] [45] [46] One of these included a single person homozygous for FVL among the 91 studied. 43 Two studies did not include a comparison group without a mutation. 35, 46 Seven studies with comparison groups enrolled 1066 family members heterozygous for FVL and 940 family members without the FVL mutation (TABLE 4). The ORs across these studies were similar except for 1 small study in which there were no events among 8 heterozygous family members. 41 The pooled OR was 3.49 (95% CI, 2.46-4.96) with little heterogeneity between studies (I 2 =0%) (FIGURE 3A) .
Removal of the study by Couturaud et al 37 increased the pooled OR to just over 4.0. In this study, the annualized event rate among family members heterozygous for FVL was 0.36% (95% CI, 0.24%-0.49%), lower than the rates in other studies. 36, 43, 45 It is unclear why VTE rates were lower in this highquality study. There was no evidence of publication bias. The inclusion of 5 studies in which relatives were not differentiated as to whether they were homozygous or heterozygous for FVL did not substantially change the OR for VTE (OR, 3.30; 95% CI, 2.49-4.39). [38] [39] [40] [47] [48] [49] Six studies described results for 48 relatives who were homozygous for FVL compared with family members (Table 3 ). Annualized rates were described for only 3 studies. [35] [36] [37] The pooled OR was 18 (95% CI, 7.8-40). The I 2 for heterogeneity was 0% ( Figure 3B6 ). One small study was excluded from pooled analyses because it had only 1 individual in each group. 42 Removal of 1 study 44 decreased the pooled OR to 16. In this study, 5 of the 6 relatives who were homozygous for FVL had venous thromboembolic events. 44 The annualized rate was not described for the mutation-free comparison group. There was no evidence of publication bias.
Four studies described venous thromboembolic events in 59 family members with double heterozygosity 37, 41, 42, 50 compared with 674 family members without mutations. One study observed no events in either group 42 (Table 4 ). The pooled OR was 6.7 (95% CI, 2.9-16), with an I 2 value of 0%. The OR for family members with double heterozygosity in 1 study was higher than in the remaining studies (OR, 8.0; 95% CI, 2.8-23). 50 This may be due to low event rates among family members without mutations (0.07% per year). This compares with somewhat higher rates in the mutation-free relatives in the other studies, ranging from 0% to 0.34%. [34] [35] [36] [37] 39, 42, 44, [46] [47] [48] Analysis suggested potential publication bias, with a paucity of small studies reporting large effect sizes.
Family members who were heterozygous for prothrombin G20210A were compared with family members without the mutation in 3 studies 37, 41, 51 ( Table 4) . In 1 study, the age-adjusted relative event rate was 3.4 (95% CI, 0.2-56) compared with family members without the mutation. 51 Remaining studies were small. 37, 41 Pooling these small studies yielded an OR for events of 1.89 (95% CI, 0.35-10), with an I 2 of 0%, suggesting that family members who are heterozygous for this mutation do not have an increased odds of thrombosis.
A single study with a comparison group described 1 relative who was homozygous for prothrombin G20210A. 41 This individual was identified among 44 family members from 4 families. None reported a venous thromboembolic event.
Three studies described agespecific event rates. 43, 45, 49 One additional study described the age of the individuals at the time of their first thrombosis among family members with and without mutations. 44 Middeldorp et al 45 described age-specific relative event rates for family members who were homozygous or heterozygous for FVL mutation or who had both FVL and prothrombin G20210A mutations compared with family members without mutations. The relative risk associated with a mutation was highest in the youngest patients (aged 15-30 years; relative rate of approximately 15) and was lowest in the older patients (relative rate of approximately 2.5). However, other similarly designed studies did not demonstrate this ageϫmutation interaction.
43,49
Impact of Testing and Resultant Management on VTE-Related Outcomes
No studies directly addressed the effect of testing on outcomes. Four studies described VTE recurrence rates during anticoagulation among probands with FVL or prothrombin G20210A. 22, 24, 29, 52 This is relevant to our question if clinicians alter anticoagulation management based on a positive test result. Three of these studies consisted of individuals participating in randomized controlled trials. 22, 24, 52 The fourth was within a prospective cohort study. 29 Two studies investigated the effect of warfarin on recurrence rates 24, 52 and 1 the effect of ximelagatran, 22 and 1 did not specify the treatment 29 (TABLE 5) . Ridker et al 52 assessed thromboembolism recurrence rates among individuals with FVL or prothrombin G20210A treated with low-intensity warfarin or placebo. Of 77 patients with FVL or prothrombin G20210A in the placebo group, 14 had recurrences (8.6 events per 100 person-years) compared with 3 of 66 assigned to the war- Family members homozygous for factor V Leiden mutation B Test for heterogeneity: I 2 = 0%; P = .58 Test for overall effect: P <.001
Test for heterogeneity: I 2 = 0%; P = .93 Test for overall effect: P <.001
Size of the data markers is proportional to study size. CI indicates confidence interval. Data not shown for Simioni et al, 42 which had no events in either group.
farin group (2.2 events per 100 personyears). Low-intensity warfarin reduced the rate of recurrence among patients with thrombophilia by 75% (hazard ratio, 0.25; 95% CI, 0.07-0.85). This risk reduction was not significantly different than the 58% reduction seen among patients without either mutation (hazard ratio, 0.42; 95% CI, 0.20-0.86; P = .51 for interaction). Kearon et al 24 studied whether VTE recurrence rates differed among individuals with vs without thrombophilic defects receiving low-intensity (international normalized ratio goal, 1.5-2.0) or conventional (international normalized ratio, goal, 2.0-3.0) warfarin therapy. Among 171 patients with FVL, 3 had recurrences. None occurred in the 60 patients with prothrombin G20210A. The recurrence rate for patients with FVL receiving lowor conventional-intensity warfarin therapy was 0.8% per year (95% CI, 0.2- P value not reported). The relative reduction in recurrence with treatment was similar for individuals with vs without FVL (P = .92 for interaction). Results were similar for individuals with prothrombin G20210A (P = .98 for interaction).
Vossen et al 29 studied the recurrence rates of VTE among probands belonging to families with thrombophilia according to whether they were receiving long-term anticoagulation. Of 304 patients, 124 were receiving longterm anticoagulation and 180 were not. Fewer FVL carriers were in the longterm anticoagulation group than in the comparison group (13% and 44%, respectively). Of 79 patients with FVL who did not receive long-term anticoagulation, 13 had recurrences during 366 person-years (incidence rate, 3.5% per year; 95% CI, 1.9-6.1). Among the 13 FVL carriers who received anticoagulation, none had recurrences during 43 person-years. There were important differences in the baseline characteristics and duration of follow-up between the 2 groups and few details about the anticoagulation regimens. 
Effect of Testing and Results on Other Outcomes
Four studies addressed how probands' and family members' knowledge, behaviors and health care experiences were affected by their being tested for FVL or prothrombin G20210A (TABLE 6) . 53 55, 56 assessed the level of understanding of the testing process and the implications of the results among probands and relatives referred for FVL. Testing had minimal impact on knowledge or behavior and was associated with no more than modest distress.
COMMENT
Moderate evidence supports that both homozygosity and heterozygosity for FVL are predictive of recurrent VTE among individuals who have had a prior VTE. Homozygosity for prothrombin G20210A is a rare genotype and its association with recurrent venous thrombosis in probands is little known. Moderate evidence supports that heterozygosity for prothrombin G20210A in probands is not predictive of recurrent VTE. Evidence is insufficient about double heterozygosity in probands.
High-grade evidence supports that homozygosity for FVL in family members predicts a higher rate of incident VTE. Moderate evidence supports that heterozygosity for FVL predicts a higher rate of incident VTE. Evidence is insufficient about risk of VTE among family members who are homozygous or heterozygous for prothrombin G20210A. Low-grade evidence supports that double heterozygosity among relatives is associated with higher risk of VTE.
There is no direct evidence that testing for these mutations, and the resultant management, reduces VTE relatedoutcomes in individuals who have had VTE or in the probands' family members who have been tested. We identified studies demonstrating that treatment reduces recurrent events in patients with FVL or prothrombin G20210A; however, the magnitude of this relative reduction is comparable with that seen in individuals without mutations. This suggests that other nongenetic factors may be as important as the presence or absence of the FVL or prothrombin G20210A mutation in determining the risk of recurrence and the absolute magnitude of benefit conferred by anticoagulation. This may be especially so in individuals with idiopathic VTE. We conclude that the incremental value of testing individuals with VTE for these mutations is uncertain. The literature does not conclusively show that testing individuals with VTE or their family members for FVL or prothrombin G20210A confers other harms or benefits. If testing is done in conjunction with education, it may increase knowledge about risk factors for VTE.
This review has limitations, including the use of only English-language articles. Furthermore, we included observational studies knowing that confounding is a possibility, particularly if there were factors that might have been associated with both the exposure (mutation status) and the outcome (thrombosis). We were limited to the covariates reported in each study, and the studies did not often present patient-level data that would allow testing for potential confounders. For the family studies, the expected confounder would be genes that are coinherited with the mutation of interest. For both the proband studies and family studies, there might be nongenetic factors such as more aggressive surveillance for events that might bias the estimate of the association between the mutation and outcome. In the studies that did report group-level data (eg, mean duration of anticoagulation or mean age at diagnosis by mutation status), we did not see any consistent evidence that these factors affected the outcomes, but we cannot definitively exclude confounding.
Studies are needed to measure how practice actually changes in response to results from FVL or prothrombin G20210A testing and whether that improves patient outcomes. Future studies should focus on whether management decisions based on testing results affect the recurrence rates (as well as complication rates) in carriers of each of these mutations. Ideally, future trials would randomize patients with thrombosis or family members of individuals with mutations to a test group or a no-test group, and individuals would be managed by their physicians based on the results of the testing, perhaps with evidence-based guidance. Studies of clinical validity should include event rates over time (and relative rates of recurrence between specified groups) rather than just the number of events. Studies should consistently differentiate between heterozygosity and homozygosity. By examining specific subsets of patients, it may be possible to clarify whether there are any interactions between mutation status and clinical variables in predicting recurrence. The data presented in the studies were insufficient to definitively exclude the effect of confounders on the relationship between the mutations and the outcome.
Uncertainty remains about the magnitude of risk for family members with mutations given the very wide CIs surrounding the ORs and the small number of studies the reported event rates (rather than counts). The studies that we included were exclusively studies of European populations. Future research would be appropriate in white populations outside of Europe or in other populations with appreciable frequencies of mutations.
